Mesothelioma News

Researchers from Leeds in the UK have reported that the incidence of mesothelioma is increasing and that the prognosis is worse than ascertained in selected studies from referral institutions. The details of this study appeared in an early online publication in Thorax on January 17, 2008.1
Most of the recent publications concerning malignant mesothelioma involve clinical […]

Steve Clairk
April 15, 2008
Madison, Wis. - Is there cause for concern at Madison-based Quintessence Bioscience? After all, Alfacell Corp., an East Coast biotech competitor, just finished its second Phase III trial of a new class of anti-cancer therapy that is very similar to what is being developed at Quintessence, which has not even begun clinical […]

SOMERSET, N.J., April 2, 2008, 2008 /PRNewswire-FirstCall via COMTEX/ — Alfacell Corporation (Nasdaq: ACEL) today announced that it has confirmed that 316 evaluable events (patient deaths) have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), for the treatment of patients with unresectable malignant mesothelioma (UMM). In accordance with the […]

Researchers from Columbia University have reported that combined resection, intraperitoneal chemotherapy, and whole abdominal radiation therapy is effective treatment for malignant peritoneal mesothelioma. The details of this study were reported in the February 2008 issue of the American Journal of Clinical Oncology.1
Peritoneal mesothelioma is much less common than pleural mesothelioma, making up less than 20% […]

By Ed Susman
FORT LAUDERDALE, FL — February 1, 2008 — Patients who underwent the more extensive treatment of radical decortication/pleurectomy in attempt to cure stage 3 pure epithelial mesothelioma appear to have significantly better outcomes than patients who had less extensive operations, according to a study presented here at the Society of Thoracic Surgeons 44th […]

Extrapleural Pneumonectomy, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma

This study is currently recruiting participants.

Verified by Dana-Farber Cancer Institute, December 2007

[…]

NEW YORK NOV 08, 2007 (Reuters Health) - High-dose vinflunine, a novel microtubule inhibitor, provides encouraging response and survival rates in patients with malignant
pleural mesothelioma, according to a report in the October 20th issue of the Journal of Clinical Oncology.
Although numerous systemic
treatments have been evaluated malignant
pleural mesothelioma, the authors explain, response […]

ACµRay(tm) sensor chip developed by Georgia Tech researchers for early detection of cancer. Credit: AACR
Cancer-sensing devices built as cheaply and efficiently as wristwatches – using many of the same operating principles – could change the way clinicians detect, treat and monitor cancer in patients. Researchers from the Georgia Institute of Technology have created an […]

This study is currently recruiting participants.Verified by National Cancer Institute (NCI) August 2007

Sponsors and Collaborators:

North Central Cancer Treatment GroupNational Cancer Institute (NCI)

Information provided by:

National Cancer Institute (NCI)

ClinicalTrials.gov Identifier:

NCT00459862

Purpose

RATIONALE: Pazopanib may stop the growth of tumor […]

By Peggy Peck, Managing Editor, MedPage Today
June 06, 2007
MedPage Today Action Points
* Explain to patients that two pemetrexed-platinum combinations demonstrated similar activity in unresectable malignant pleural mesothelioma.
* Note that the findings came from an expanded access program for pemetrexed rather than a randomized clinical trial.
[…]